Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

To Learn More Call
201-510-0910

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor
Karyopharm

Protocol Number
Karyppharm KCP-8602-801

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Onyx

Protocol Number
CFZ013

To Learn More Call
201-510-0910

Exploring the clinical relevance of matriptase expression in multiple myeloma

Sponsor
Georgetown

Protocol Number
Georgetown CCSG Pilot Project

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Amgen

Protocol Number
20160275

To Learn More Call
201-510-0910

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-001

To Learn More Call
201-510-0910

Collection of Biological Specimen

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Collection of Buological Specimen

To Learn More Call
201-510-0910

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
Celgene

Protocol Number
BB2121-MM-001

To Learn More Call
201-510-0910

A Phase I, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics Effects of Orally Administered CB-5083 in patients with Relapsed-Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Cleave Bioscience

Protocol Number
CLC-102

T